药品注册申请号:205993
申请类型:ANDA (仿制药申请)
申请人:PADAGIS US
申请人全名:PADAGIS US LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ No No AB2 2015/11/05 2015/11/05 Prescription
002 POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ No No AB2 2015/11/05 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2020/04/26 SUPPL-3(补充) Approval Labeling STANDARD
2015/11/05 ORIG-1(原始申请) Approval STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:POTASSIUM CHLORIDE 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:8MEQ 治疗等效代码:AB2
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
019123 001 NDA KLOR-CON POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription Yes No AB2 1986/04/17 UPSHER SMITH LABS
204662 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2014/08/21 MYLAN
205993 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2015/11/05 PADAGIS US
206759 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2016/08/09 NOVEL LABS INC
209314 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2018/06/22 YICHANG HUMANWELL
210733 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2018/08/31 STRIDES PHARMA
210921 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2018/12/19 AUROBINDO PHARMA
211797 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2020/03/04 GRANULES
217412 001 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 8MEQ Prescription No No AB2 2023/12/19 RISING
活性成分:POTASSIUM CHLORIDE 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:10MEQ 治疗等效代码:AB2
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
019123 002 NDA KLOR-CON POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription Yes Yes AB2 1986/04/17 UPSHER SMITH LABS
204662 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2014/08/21 MYLAN
205993 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2015/11/05 PADAGIS US
206759 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2016/08/09 NOVEL LABS INC
209314 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2018/06/22 YICHANG HUMANWELL
210733 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2018/08/31 STRIDES PHARMA
210921 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2018/12/19 AUROBINDO PHARMA
211797 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2020/03/04 GRANULES
217412 002 ANDA POTASSIUM CHLORIDE POTASSIUM CHLORIDE TABLET, EXTENDED RELEASE;ORAL 10MEQ Prescription No No AB2 2023/12/19 RISING
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database